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Interleukin-6 (IL-6) is a pleiotropic cytokine that exerts either proinflammatory or anti-inflammatory effects
and is implicated in diverse settings, including obesity, exercise, arthritis, and colitis. A new study shows
that modulation of macrophage activation by IL-6 maintains glucose homeostasis in diet-induced obesity
while limiting inflammation in endotoxemia (Mauer et al., 2014).Interleukin-6 (IL-6) is generally considered
a proinflammatory cytokine, as it pro-
motes neutrophilia and T helper 17
(Th17) T cell differentiation while blocking
regulatory T cell (Treg) differentiation. IL-6
critically contributes to pathophysiology
of several inflammatory diseases, includ-
ing rheumatoid arthritis and experimental
autoimmune encephalomyelitis. How-
ever, an immunoregulatory role for IL-6
has also been suggested in specific con-
texts. For instance, genetic deficiency of
IL-6 increases inflammatory responses
to local and systemic endotoxin adminis-
tration. Muscle-derived IL-6 may also
mediate some of the anti-inflammatory
and insulin-sensitizing effects of physical
exercise. Thus, available evidence is
consistent with pleiotropic functions for
the cytokine (Scheller et al., 2011). Impor-
tantly, how IL-6 regulates macrophage
biology remains poorly understood. This
is in striking contrast to IL-10, a cytokine
that signals similarly to IL-6 but serves
as a paradigm for immunoregulation of
macrophage activation. In a new study,
Mauer et al. (2014) make the unexpected
and important finding that while IL-6
potentiates alternative (M2) macrophage
activation by IL-4, resulting in improved
metabolic responses to high-fat diet chal-
lenge, it attenuates classical (M1) macro-
phage activation to lipopolysaccharide
(LPS), thus conferring protection to endo-
toxemia (Mauer et al., 2014).
Mauer et al. (2014) first investigated the
role of IL-6 in controlling macrophage
activation in the context of metabolic
homeostasis, where the modality of
macrophage activation is known to be
critical. M2 activation of adipose tissue
macrophages, mediated by IL-4 and/or
IL-13 production from eosinophils and/or
ILC2 cells, favors insulin sensitivity. On
the other hand, M1 activation, triggered898 Cell Metabolism 19, June 3, 2014 ª2014by saturated fatty acids and/or adipo-
cyte-derived inflammatory cytokines,
contributes to obesity-associated chronic
inflammation (or metaflammation), insulin
resistance, and systemic metabolic dete-
rioration (Chawla et al., 2011; Gregor and
Hotamisligil, 2011). The authors found
that despite comparable food intake and
weight gain, mice with myeloid-specific
deletion of IL-6ra (IL6raDmyel) were more
glucose intolerant and insulin resistant
on a high-fat diet. This may be a result of
increased metaflammation in white adi-
pose tissue (WAT), brown adipose tissue,
and liver, as indicated by increased ex-
pression of markers of M1 macrophages,
while expression of M2 markers was
reduced (Mauer et al., 2014).
To elucidate the basis for such modu-
lation of macrophage activation, the
authors used microarray analysis to
identify IL-6-regulated responses (Mauer
et al., 2014). Interestingly, IL-4ra, which
encodes the IL-4 receptor binding both
IL-4 and IL-13, emerged as one of the
most strongly inducible genes in IL-6-
stimulated bone marrow-derived macro-
phages (BMDMs) and was identified as a
direct target of Stat3, the major transcrip-
tion factor activated by IL-6 signaling.
Accordingly, IL-6 increased IL-4-medi-
ated induction of multiple M2 genes
in vitro and in vivo. In addition, IL-4ra
expression in WAT was reduced in obese
IL6raDmyel mice, which dovetails nicely
with the relative inability of exogenous
IL-4 to improve glucose tolerance in these
mice. Conversely, Mauer et al. (2014)
showed that IL-6 exerts opposing effects
on M1 activation, since pretreatment of
BMDMs with IL-6 attenuated LPS-
mediated induction of multiple genes,
including TNFa and Nos2. Indeed,
IL6raDmyel mice were more susceptible
to LPS-induced endotoxemia, as indi-Elsevier Inc.cated by increased plasma levels of
proinflammatory cytokines, and exacer-
bated weight loss and reduced food
intake. Collectively, these findings estab-
lish a role for IL-6 in promoting M2
activation while attenuating M1 activation
(Figure 1).
The study by Mauer et al. (2014) sug-
gests that IL-6 may modulate macro-
phage activation during diet-induced
obesity to attenuate inflammatory re-
sponses and resist metabolic dysregula-
tion. In the obese state, increased IL-6
production (Pedersen and Febbraio,
2007) may be an adaptive response to
metabolic stress. Because IL-6 is pro-
duced by many cell types and tissues
and secreted into the circulation, the
potential sources are manifold and could
include adipocytes and the liver. Such
IL-6 production potentiates M2 activation
of adipose tissue macrophages by IL-4
and presumably IL-13, which also signals
through IL-4Ra. In parallel, IL-6 may
dampen M1 activation by saturated fatty
acids and LPS, and perhaps other in-
flammatory cytokines, all of which are
elevated in obesity. Thus, IL-6 may be
produced as a negative feedback mecha-
nism during chronic nutrient excess to
tune macrophage activation (Figure 1).
The complex and nuanced functions
of IL-6 may explain the conflicting litera-
ture on its role in metabolic regulation,
with some studies supporting beneficial
effects and others indicating detrimental
activities (Pedersen and Febbraio, 2007).
For example, IL-6-deficient mice develop
mature-onset obesity in one study, but
not another, while acute infusion of IL-6
can impair insulin sensitivity or enhance
glucose tolerance. Notably, the emerging
view of IL-6 as both an immunoregulatory
and proinflammatory cytokine is con-
sistent with its dual roles in catabolic
Figure 1. IL-6 Limits Obesity-Induced Insulin Resistance by Promoting Macrophage M2
Polarization
In the obese state, increased production of IL-6 promotes M2 activation of adipose tissue macrophages
by upregulating the expression of IL-4ra. In parallel, IL-6 may inhibit the effects of saturated fatty acids
(SFAs) and lipopolysaccharide (LPS) in triggering M1 activation. Thus, IL-6 regulates activation of adipose
tissuemacrophages to attenuate inflammatory responses, improve insulin sensitivity, and resist metabolic
dysregulation.
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(e.g., increasing insulin sensitivity) meta-
bolism. While the complexities of IL-6
function will take more time to sort out,
one intriguing possibility is that its source,
target, and circulating levels can deter-
mine its proinflammatory versus immuno-
regulatory effects. In this regard, it has
been proposed that IL-6 signaling via the
classical pathway (through IL-6Ra and
gp130) and in trans (by binding of an IL-6
and soluble IL-6Ra complex to cell sur-
face gp130) may lead to different out-
comes (Scheller et al., 2011).
The findings of Mauer et al. (2014) raise
additional interesting points for discus-
sion. While IL-4Ra upregulation would
undoubtedly sensitize macrophages to
IL-4, IL-6 is likely to promote M2 acti-
vation via additional mechanisms, for
example via AMP-activated protein ki-
nase (AMPK) and/or phosphatidylinositol
3-kinase (PI3K)/Akt activation, which areimplicated in macrophage polarization to
an M2 or anti-inflammatory phenotype.
Such mechanisms could allow for modu-
lation of specific subsets of M2 genes,
as opposed to IL-4ra induction, which
may increase induction of all M2 genes.
Regardless of the underlying mechanism,
knowingwhether IL-6 synergizes with IL-4
in the induction of a subset or the entirety
of theM2 programmay offer additional in-
sights into the rationale of M2 activation
by IL-6. How IL-6 negatively regulates
M1 activation would also be important to
explore. Finally, does IL-6 regulate M2
activation in other physiological and path-
ophysiological contexts? Exercise, cold
stress, and fasting have all been shown
to increase circulating levels of IL-6, and
M2 activation in these contexts may
promote muscle regeneration, adaptive
thermogenesis, and lipid scavenging,
respectively (Kosteli et al., 2010; Nguyen
et al., 2011; Pillon et al., 2013; WernstedtCell Metabolismet al., 2006; Wueest et al., 2014). Related
to this, IL-6 can stimulate whole-body and
intramyocellular fatty acid oxidation as
well as lipolysis (Pedersen and Febbraio,
2007). Since beta-oxidation supports M2
activation (as opposed to glycolytic meta-
bolism in the case of M1 macrophages)
(Chawla et al., 2011), such effects of IL-6
would enable coordination of M2 activa-
tion with the systemic metabolic profile.
Despite its discovery nearly 30 years
ago, how IL-6 controls macrophage
biology has remained poorly understood.
The study byMauer et al. (2014) highlights
the role of IL-6 as an important regulator
of macrophage activation and is sure to
spark new interest in this fascinating
cytokine.
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